Precision gut microbiome startup AMILI gets funding boost from East Ventures


AMILI, the first and only precision gut microbiome company in Southeast Asia, has announced that it has secured additional funding from East Ventures, a renowned venture capital firm supporting numerous tech companies across Southeast Asia.

This funding reinforces AMILI’s financial position following its series A funding in June 2022. The newly acquired funds will be allocated to expand operations into Indonesia, with a primary focus on addressing prevalent gut health issues using scientific approaches tailored to the Indonesian context.

Dr. Jeremy Lim, Co-Founder and CEO of AMILI, expressed gratitude for the partnership with East Ventures, emphasizing the company’s commitment to enabling healthcare professionals to leverage microbiome science for the benefit of their patients.

In addition to healthcare, AMILI aims to contribute to innovations in the food and agritech sectors, particularly in the development of health-enhancing foods and addressing issues like stunting and malnutrition.

Scientific advancements have highlighted the gut microbiome as the next frontier in human health. Comprised of trillions of bacteria, viruses, and fungi residing in the digestive tract, the gut microbiome plays a vital role in digestion, immune function, mental health, and disease prevention.

The emerging applications of the gut microbiome present new opportunities for personalized medicine and transformative healthcare approaches.

Founded in 2019 by Dr. Jeremy Lim, along with Drs. David Ong and Jonathan Lee, AMILI conducts advanced gut microbiome research and translates it into products and services.

Their current offerings include gut microbiome sequencing services to support healthcare professionals in delivering enhanced patient care, as well as probiotic formulations specifically designed for Asian consumers.

AMILI also operates Southeast Asia’s only microbiome transplant bank and has facilitated transplants across the region.

Willson Cuaca, Co-Founder and Managing Partner at East Ventures, expressed excitement over supporting AMILI in advancing precision medicine and personalized health and nutrition through harnessing the potential of the gut microbiome.

By conducting localized studies and understanding the intricacies of the Asian gut microbiome, the partnership aims to develop insights and interventions tailored to the needs and challenges of the Asian population, ultimately improving individual health and well-being in the region.

AMILI has been at the forefront of microbiome-led applications since its inception. Through collaborations with regional research partners, AMILI has built the world’s largest multi-ethnic microbiome database, enabling the development of innovative offerings such as Singapore’s first at-home gut microbiome testing service and the region’s first probiotic blend incorporating prebiotics and postbiotics.

Last year, the company also co-developed a sustainable prebiotic powder by upcycling unused kale stalks.